WO2023116574A1 - Anticorps anti-c5a isolé, sa préparation et son utilisation - Google Patents

Anticorps anti-c5a isolé, sa préparation et son utilisation Download PDF

Info

Publication number
WO2023116574A1
WO2023116574A1 PCT/CN2022/139676 CN2022139676W WO2023116574A1 WO 2023116574 A1 WO2023116574 A1 WO 2023116574A1 CN 2022139676 W CN2022139676 W CN 2022139676W WO 2023116574 A1 WO2023116574 A1 WO 2023116574A1
Authority
WO
WIPO (PCT)
Prior art keywords
buffer
antibody
tween
seq
amino acid
Prior art date
Application number
PCT/CN2022/139676
Other languages
English (en)
Chinese (zh)
Inventor
沈丙权
张雪瑾
朱萍霞
李忠
Original Assignee
舒泰神（北京）生物制药股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 舒泰神（北京）生物制药股份有限公司 filed Critical 舒泰神（北京）生物制药股份有限公司
Priority to CN202280008248.5A priority Critical patent/CN116670288A/zh
Publication of WO2023116574A1 publication Critical patent/WO2023116574A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Definitions

  • the invention belongs to the technical field of biomedicine, and in particular relates to an isolated anti-C5a antibody and its preparation and application.
  • C5a is an active peptide in allergic reactions and inflammatory processes, which is formed by the cleavage of complement component C5 by C5 convertase in the complement cascade.
  • C5a stimulates mast cell degranulation, release of tumor necrosis factor- ⁇ (TNF- ⁇ ) and histamine, and also recruits phagocytes to sites of infection and inflammation by increasing expression of endothelial cell surface adhesion molecules (Mollnes, T.E. et al. Blood 2002, 100, 1869–1877; Riedemann, N.C. et al. Immunity 2003, 19, 193–202).
  • C5a In the case of some pathological stimuli, such as post-transplant allograft rejection and asthma, C5a also leads to increased vascular permeability (Gueler, F. et al. J. Am. Soc. Nephrol. 2008, 19, 2302–2312; Krug , N. et al. Am. J. Respir. Crit. Care Med. 2001, 164, 1841–1843; Khan, M.A. et al. Proc. Natl. Acad. Sci. USA 2013, 110, 6061–6066).
  • C5a is a potent pro-inflammatory molecule that binds to a classical G protein-coupled receptor (GPCR) C5aRI (CD88) and triggers activation of pro-inflammatory signaling pathways (Li, R.
  • GPCR G protein-coupled receptor
  • C5aR is widely expressed on non-myeloid cells such as umbilical vascular endothelial cells (HUVEC), murine dermis, liver, lung and renal proximal tubules (Monsinjon, T. et al. FASEB J. 2003, 17, 1003–1014; Gerard , C. et al. Annu. Rev. Immunol. 1994, 12, 775–808; Haviland, D.L. et al. J. Immunol. 1995, 154, 1861–1869).
  • UUVEC umbilical vascular endothelial cells
  • Patent application WO2011063980 disclosed the antibody INab308 (InflaRx) against human C5a
  • WO2012088247 disclosed the C5a antibody MEDI-7814 (MedImmune)
  • US10450370 disclosed the C5a antibody BNJ383 (Alexion).
  • the present invention provides an isolated anti-C5a antibody and anti-C5a antibody preparation with strong stability for treating C5a-mediated diseases and disorders.
  • the invention provides an isolated anti-C5a antibody comprising a VH comprising: HC- CDR1 comprising the amino acid sequence of SEQ ID NO: 1, HC-CDR2 comprising the amino acid Sequence SEQ ID NO:2, and HC-CDR3, which comprises the amino acid sequence of SEQ ID NO:3; and V L , which comprises: LC- CDR1 , which comprises the amino acid sequence of SEQ ID NO:9, LC-CDR2, It comprises the amino acid sequence of SEQ ID NO: 10, and LC-CDR3, which comprises the amino acid sequence of SEQ ID NO: 11; or
  • the antibody comprises a VH comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and HC-CDR3 comprising the amino acid sequence SEQ ID NO:3; and V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:12, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:10, and LC-CDR3 comprising comprising the amino acid sequence of SEQ ID NO: 11; or
  • the antibody comprises a VH comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO:4, HC-CDR2 comprising the amino acid sequence of SEQ ID NO:5, and HC-CDR3 comprising the amino acid sequence SEQ ID NO: 6; and V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 13, LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LC-CDR3 comprising comprising the amino acid sequence of SEQ ID NO: 15; or
  • the antibody comprises a VH comprising: HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 7, HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 8, and HC-CDR3 comprising the amino acid sequence SEQ ID NO:3; and V L comprising: LC-CDR1 comprising the amino acid sequence of SEQ ID NO:16, LC-CDR2 comprising the amino acid sequence of SEQ ID NO:17, and LC-CDR3 comprising Contains the amino acid sequence of SEQ ID NO:11.
  • the antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 18, and a VL comprising the amino acid sequence of SEQ ID NO: 22; or
  • the antibody comprises a V H comprising the amino acid sequence of SEQ ID NO: 19, and a V L comprising the amino acid sequence of SEQ ID NO: 23; or
  • the antibody comprises a V H comprising the amino acid sequence of SEQ ID NO: 20, and a V L comprising the amino acid sequence of SEQ ID NO: 24; or
  • the antibody comprises a VH comprising the amino acid sequence of SEQ ID NO:21, and a VL comprising the amino acid sequence of SEQ ID NO:25.
  • the isolated anti-C5a antibody is a full length IgG antibody. In some embodiments, the isolated anti-C5a antibody is a full length IgGl or IgG4 antibody.
  • the antibody comprises a heavy chain constant region and a light chain constant region
  • the heavy chain constant region comprises the amino acid sequence shown in SEQ ID NO: 26 or 27
  • the light chain constant region comprises the amino acid sequence shown in SEQ ID NO: Amino acid sequence shown in ID NO:28.
  • the antibody comprises a VH , a VL , a heavy chain constant region and a light chain constant region, the VH comprising the amino acid sequence of SEQ ID NO: 18, and the VL comprising the amino acid sequence of SEQ ID NO: 22.
  • the heavy chain constant region comprises the amino acid sequence of SEQ ID NO:26
  • the light chain constant region comprises the amino acid sequence of SEQ ID NO:28; or
  • the antibody comprises V H , V L , a heavy chain constant region and a light chain constant region, the V H comprising the amino acid sequence of SEQ ID NO: 19, the V L comprising the amino acid sequence of SEQ ID NO: 23, the heavy chain
  • the constant region comprises the amino acid sequence of SEQ ID NO:27 and the light chain constant region comprises the amino acid sequence of SEQ ID NO:28; or
  • the antibody comprises V H , V L , a heavy chain constant region and a light chain constant region, the V H comprising the amino acid sequence of SEQ ID NO: 20, the V L comprising the amino acid sequence of SEQ ID NO: 24, the heavy chain
  • the constant region comprises the amino acid sequence of SEQ ID NO:26 and the light chain constant region comprises the amino acid sequence of SEQ ID NO:28; or
  • the antibody comprises V H , V L , a heavy chain constant region and a light chain constant region, the V H comprising the amino acid sequence of SEQ ID NO: 21, the V L comprising the amino acid sequence of SEQ ID NO: 25, the heavy chain
  • the constant region comprises the amino acid sequence of SEQ ID NO:27 and the light chain constant region comprises the amino acid sequence of SEQ ID NO:28.
  • the present invention provides an anti-C5a antibody preparation, which comprises the above-mentioned isolated anti-C5a antibody, a stabilizer, a surfactant, and a buffer.
  • the antibody concentration is 1 mg/ml-300 mg/ml; preferably, the antibody concentration is 10 mg/ml-200 mg/ml. In some specific embodiments, the concentration of the antibody is 10mg/ml, 15mg/ml, 25mg/ml, 35mg/ml, 50mg/ml, 75mg/ml, 100mg/ml, 125mg/ml, 150mg/ml, 175mg /ml or 200mg/ml.
  • the stabilizer is any one of sucrose, trehalose, maltose, sorbitol, mannitol, sodium chloride, arginine hydrochloride, glycine, proline, lysine or Several combinations. In some embodiments, the stabilizer is any one or a combination of sucrose, arginine hydrochloride, sodium chloride, mannitol, trehalose, and sorbitol.
  • the stabilizing agent is: sodium chloride, arginine hydrochloride, glycine at a concentration of 50mM-300mM, preferably 100mM-250mM (in some embodiments, at a concentration of 100mM, 150mM, 200mM or 250mM) , proline or lysine, and or a concentration of 30mg/ml-150mg/ml, preferably 45mg/ml-100mg/ml (in some embodiments, a concentration of 45mg/ml, 50mg/ml, 55mg/ml, 60mg/ml, 65mg/ml, 70mg/ml, 75mg/ml, 80mg/ml, 85mg/ml, 90mg/ml, 95mg/ml or 100mg/ml) of sucrose, trehalose, maltose, sorbitol, mannitol.
  • the buffer is histidine-histidine hydrochloride buffer, citric acid-disodium hydrogen phosphate buffer, acetic acid-sodium acetate buffer, phosphate buffer, glutamate any of the buffers.
  • the concentration of the buffer is 3mM-100mM; in some embodiments, the concentration of the buffer is 5mM-80mM or 8mM-50mM; preferably, the concentration of the buffer is 10mM- 30mM, in some embodiments, the concentration of the buffer is 10mM or 20mM or 30mM.
  • the pH of the buffer is 4.8-8.0; in some embodiments, the pH of the buffer is 5.0-7.2; in some embodiments, the pH of the buffer is 5.0, 5.5, 5.8, 6, 6.2, 6.5, 6.8, 7.0 or 7.2; preferably, the buffer solution has a pH value of 5.5-7.0.
  • the surfactant is any one or a combination of polysorbate and/or poloxamer; preferably, the polysorbate is Tween-20 or Tween-20 80.
  • the concentration of the surfactant is 0.01mg/ml-2mg/ml; preferably, the concentration of the surfactant is 0.02mgml-1.5mg/ml or 0.03mg/ml-1mg/ml Or 0.04mg/ml-0.5mg/ml; more preferably, the concentration of the surfactant is 0.05mg/ml-0.3mg/ml; in some specific embodiments, the concentration of the surfactant is 0.05mg/ml , 0.10mg/ml, 0.15mg/ml, 0.2mg/ml, 0.25mg/ml, 0.3mg/ml.
  • the formulation is any of the following formulations:
  • the antibody concentration is 10mg/ml, 15mg/ml, 25mg/ml, 35mg/ml, 50mg/ml, 75mg/ml, 100mg/ml, 125mg/ml, 150mg/ml, 175mg/ml or 200mg/ml ml;
  • the stabilizer is 100mM-250mM arginine hydrochloride and/or sodium chloride, and/or 45mg/ml-100mg/ml sucrose, trehalose, mannitol and/or sorbitol;
  • the buffer Liquid is 10mM-30mM histidine-histidine hydrochloride buffer, citric acid-disodium hydrogen phosphate buffer, acetic acid-sodium acetate buffer, phosphate buffer;
  • the pH value of the buffer is 5.5 -7.0;
  • the surfactant is Tween-20 and/or Tween-80 of 0.05mg/ml-
  • the antibody concentration is 10mg/ml-200mg/ml; the stabilizer is 100mM, 150mM, 200mM or 250mM arginine hydrochloride and/or sodium chloride, and/or 45mg/ml, 50mg sucrose, trehalose, mannitol and /or sorbitol;
  • the buffer is 10mM-30mM histidine-histidine hydrochloride buffer, citric acid-disodium hydrogen phosphate buffer, acetic acid-sodium acetate buffer, phosphate buffer;
  • the pH value of the buffer solution is 5.5-7.0; the surfactant is 0.05mg/ml-0.3mg/ml Tween-20 and/or Tween-80;
  • the antibody concentration is 10-200mg/ml;
  • the stabilizer is 100mM-250mM arginine hydrochloride and/or sodium chloride, and/or 45mg/ml-100mg/ml sucrose, seaweed Sugar, mannitol and/or sorbitol;
  • the buffer is 10mM, 20mM, 30mM histidine-histidine hydrochloride buffer, citric acid-disodium hydrogen phosphate buffer, acetic acid-sodium acetate buffer, Phosphate buffer;
  • the pH value of the buffer is 5.5-7.0;
  • the surfactant is Tween-20 and/or Tween-80 of 0.05mg/ml-0.3mg/ml;
  • the antibody concentration is 10-200mg/ml; the stabilizer is 100mM-250mM arginine hydrochloride and/or sodium chloride, and/or 45mg/ml-100mg/ml sucrose, seaweed Sugar, mannitol and/or sorbitol;
  • the buffer is 10mM-30mM histidine-histidine hydrochloride buffer, citric acid-disodium hydrogen phosphate buffer, acetic acid-sodium acetate buffer, phosphate Buffer; the pH value of the buffer is 5.5, 5.8, 6, 6.2, 6.5, 6.8 or 7.0; the surfactant is Tween-20 and/or Tween of 0.05mg/ml-0.3mg/ml -80;
  • the antibody concentration is 10-200mg/ml; the stabilizer is 100mM-250mM arginine hydrochloride and/or sodium chloride, and/or 45mg/ml-100mg/ml sucrose, seaweed Sugar, mannitol and/or sorbitol;
  • the buffer is 10mM-30mM histidine-histidine hydrochloride buffer, citric acid-disodium hydrogen phosphate buffer, acetic acid-sodium acetate buffer, phosphate buffer; the pH of the buffer is 5.5-7.0; the surfactant is 0.05mg/ml, 0.10mg/ml, 0.15mg/ml, 0.2mg/ml, 0.25mg/ml or 0.3mg/ml Tween-20 and/or Tween-80.
  • the formulation is any of the following formulations:
  • the preparation comprises the anti-C5a antibody of 10mg/ml-200mg/ml, the histidine-histidine hydrochloride buffer of 10mM-30mM, the arginine hydrochloride of 100mM-250mM, 0.05mg/ ml-0.3mg/ml of Tween 20 or Tween 80, the pH of the buffer is 5.5-7.0;
  • the preparation comprises 10mg/ml-200mg/ml anti-C5a antibody, 10mM-30mM histidine-histidine hydrochloride buffer, 100mM-250mM sodium chloride, 0.05mg/ml-0.3 mg/ml of Tween 20 or Tween 80, the pH of the buffer is 5.5-7.0;
  • the preparation comprises 10mg/ml-200mg/ml anti-C5a antibody, 10mM-30mM histidine-histidine hydrochloride buffer, 45mg/ml-100mg/ml sucrose, 0.05mg/ml - 0.3mg/ml of Tween 20 or Tween 80, the pH of the buffer is 5.5-7.0;
  • the preparation comprises 10mg/ml-200mg/ml anti-C5a antibody, 10mM-30mM acetate buffer, 100mM-250mM arginine hydrochloride, 0.05mg/ml-0.3mg/ml Tween 20 or Tween 80, the pH value of the buffer is 5.5-7.0
  • the preparation comprises 10mg/ml-200mg/ml anti-C5a antibody, 10mM-30mM acetate buffer, 100mM-250mM sodium chloride, 0.05mg/ml-0.3mg/ml Tween 20 Or Tween 80, the pH value of the buffer is 5.5-7.0;
  • the preparation comprises 10mg/ml-200mg/ml anti-C5a antibody, 10mM-30mM acetate buffer, 45mg/ml-100mg/ml sucrose, 0.05mg/ml-0.3mg/ml spit Wen 20 or Tween 80, the pH value of the buffer solution is 5.5-7.0;
  • the preparation comprises 10mg/ml-200mg/ml anti-C5a antibody, 10mM-30mM phosphate buffer saline, 100mM-250mM arginine hydrochloride, 0.05mg/ml-0.3mg/ml Wen 20 or Tween 80, the pH value of the buffer solution is 5.5-7.0;
  • the preparation comprises 10mg/ml-200mg/ml anti-C5a antibody, 10mM-30mM phosphate buffer, 100mM-250mM sodium chloride, 0.05mg/ml-0.3mg/ml Tween 20 or Tween 80, the pH value of the buffer solution is 5.5-7.0;
  • the preparation comprises 10mg/ml-200mg/ml anti-C5a antibody, 10mM-30mM phosphate buffer, 45-100mg/ml sucrose, 0.05mg/ml-0.3mg/ml Tween 20 or Tween 80, the pH value of the buffer solution is 5.5-7.0;
  • the preparation comprises 10mg/ml-200mg/ml anti-C5a antibody, 10mM-30mM citric acid-disodium hydrogen phosphate buffer, 100mM-250mM arginine hydrochloride, 0.05mg/ml-0.3 mg/ml of Tween 20 or Tween 80, the pH of the buffer is 5.5-7.0;
  • the preparation comprises 10mg/ml-200mg/ml anti-C5a antibody, 10mM-30mM citric acid-disodium hydrogen phosphate buffer, 100mM-250mM sodium chloride, 0.05mg/ml-0.3mg/ml Tween 20 or Tween 80, the pH value of the buffer is 5.5-7.0;
  • the preparation comprises 10mg/ml-200mg/ml anti-C5a antibody, 10mM-30mM citric acid-disodium hydrogen phosphate buffer, 45-100mg/ml sucrose, 0.05mg/ml-0.3mg/ml Tween 20 or Tween 80, the pH value of the buffer is 5.5-7.0;
  • the preparation comprises 10mg/ml-200mg/ml anti-C5a antibody, 10mM-30mM histidine-histidine hydrochloride buffer, 45mg/ml-100mg/ml mannitol or sorbitol or Trehalose, 0.05mg/ml-0.3mg/ml Tween 80, the pH value of the buffer solution is 5.5-7.0.
  • the formulation is any of the following formulations:
  • the preparation comprises the anti-C5a antibody of 15mg/ml, the histidine-histidine hydrochloride buffer of 20mM, the arginine hydrochloride of 150mM, the Tween 80 of 0.1mg/ml, the described
  • the pH of the buffer is 6.2;
  • the preparation comprises the anti-C5a antibody of 10mg/ml, the histidine-histidine hydrochloride buffer of 10mM, the arginine hydrochloride of 200mM, the Tween 20 of 0.15mg/ml, the described
  • the pH of the buffer is 6.4;
  • the preparation comprises the anti-C5a antibody of 15mg/ml, the histidine-histidine hydrochloride buffer of 30mM, the arginine hydrochloride of 150mM, the Tween 80 of 0.05mg/ml, the described
  • the pH of the buffer is 5.8;
  • the preparation comprises the anti-C5a antibody of 15mg/ml, the histidine-histidine hydrochloride buffer solution of 20mM, the sodium chloride of 150mM, the Tween 80 of 0.1mg/ml, the Tween 80 of described buffer solution
  • the pH value is 6.0;
  • the preparation comprises 15 mg/ml of anti-C5a antibody, 10 mM acetate buffer, 250 mM arginine hydrochloride, 0.1 mg/ml Tween 80, and the pH value of the buffer is 6.2 ;
  • the preparation comprises 15 mg/ml of anti-C5a antibody, 20 mM phosphate buffer, 100 mM arginine hydrochloride, 0.1 mg/ml Tween 80, and the pH of the buffer is 6.0;
  • the preparation comprises the anti-C5a antibody of 15mg/ml, the histidine-histidine hydrochloride buffer solution of 20mM, the sucrose of 100mg/ml, the Tween 80 of 0.2mg/ml, the pH of the buffer solution The value is 6.8;
  • the preparation comprises the anti-C5a antibody of 15mg/ml, the histidine-histidine hydrochloride buffer solution of 20mM, the mannitol of 50mg/ml, the Tween 80 of 0.1mg/ml, the Tween 80 of the buffer solution
  • the pH value is 6.0;
  • the preparation comprises the anti-C5a antibody of 15mg/ml, the histidine-histidine hydrochloride buffer solution of 20mM, the sorbitol of 45mg/ml, the Tween 80 of 0.1mg/ml, the Tween 80 of described buffer solution
  • the pH value is 7.0;
  • the preparation comprises the anti-C5a antibody of 30mg/ml, the histidine-histidine hydrochloride buffer solution of 20mM, the trehalose of 80mg/ml, the Tween 80 of 0.1mg/ml, the Tween 80 of described buffer solution
  • the pH value is 6.2;
  • the preparation comprises the anti-C5a antibody of 50mg/ml, the histidine-histidine hydrochloride buffer solution of 30mM, the sucrose of 60mg/ml, the Tween 80 of 0.1mg/ml, the pH of the buffer solution Value is 6.0;
  • the preparation comprises the anti-C5a antibody of 100mg/ml, the histidine-histidine hydrochloride buffer solution of 20mM, the sucrose of 50mg/ml, the Tween 80 of 0.1mg/ml, the pH of the buffer solution Value is 6.0;
  • the preparation comprises the anti-C5a antibody of 150mg/ml, the histidine-histidine hydrochloride buffer solution of 20mM, the sucrose of 60mg/ml, the Tween 80 of 0.2mg/ml, the pH of the buffer solution Value is 6.0;
  • the preparation comprises the anti-C5a antibody of 200mg/ml, the histidine-histidine hydrochloride buffer solution of 20mM, the sucrose of 70mg/ml, the Tween 80 of 0.3mg/ml, the pH of the buffer solution Value is 6.0;
  • the preparation comprises 150 mg/ml of anti-C5a antibody, 20 mM phosphate buffer, 150 mM arginine hydrochloride, 0.2 mg/ml Tween 80, and the pH of the buffer is 5.5;
  • the preparation comprises 150 mg/ml of anti-C5a antibody, 20 mM citric acid-disodium hydrogen phosphate buffer, 100 mM sodium chloride, 0.1 mg/ml Tween 20, and the pH of the buffer is 5.8;
  • the preparation comprises the anti-C5a antibody of 150mg/ml, the histidine-histidine hydrochloride buffer solution of 10mM, the sodium chloride of 200mM, the Tween 80 of 0.2mg/ml, the Tween 80 of described buffer solution
  • the pH is 6.8.
  • the formulations may also include preservatives and/or antioxidants.
  • the preservative or antioxidant is a preservative or antioxidant commonly used in antibody preparations.
  • the preservative is ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTPA) or a combination thereof; the antioxidant is methionine.
  • the concentration of the preservative is 0-0.5 mg/ml, in some specific embodiments, the concentration of the preservative is 0 mg/ml, 0.02 mg/ml, 0.15 mg/ml, 0.25 mg/ml , 0.4ml/ml or 0.5mg/ml. In some embodiments, the concentration of the antioxidant is 0-1.1 mg/ml. In some embodiments, the concentration of the antioxidant is 0 mg/ml, 0.15 mg/ml, 0.75 mg/ml or 0.11 mg/ml.
  • the above-mentioned antibody preparation is a liquid preparation or a powder for injection.
  • the present invention provides the use of any anti-C5a antibody and any anti-C5a antibody preparation described above in the preparation of a drug for treating diseases.
  • the invention provides a method of treating a disease or condition in an individual in need thereof, comprising administering to said individual an effective amount of any one of the anti-C5a antibodies or antibody preparations described above.
  • the administration methods include: intravenous injection, intraarterial administration, intraperitoneal injection, intrapulmonary administration, oral administration, inhalation administration, intravascular administration, intramuscular injection, intratracheal administration, subcutaneous injection, intraocular administration , intrathecal, mucosal or transdermal administration.
  • the formulation is administered intravenously.
  • the formulation is administered subcutaneously.
  • the formulation is administered intramuscularly.
  • the disease or condition is an inflammatory, respiratory or autoimmune disease or condition; preferably, the disease is selected from the group consisting of inflammatory response syndrome (SIRS), sepsis, severe sepsis, septic shock, Blood/reperfusion-related injury, acute lung injury, pneumonia, acute and chronic graft rejection in transplant patients, graft-versus-host reaction, glomerular disease, glomerulonephritis, solid renal failure, rheumatoid arthritis, autoimmunity disease, Bechterew's disease, lupus-like disease, inflammatory bowel disease, Crohn's disease, tumor growth, and solid organ cancer.
  • SIRS inflammatory response syndrome
  • sepsis severe sepsis
  • septic shock Blood/reperfusion-related injury
  • acute lung injury acute lung injury
  • pneumonia acute and chronic graft rejection in transplant patients
  • graft-versus-host reaction glomerular disease
  • glomerulonephritis solid renal failure
  • rheumatoid arthritis
  • the anti-C5a antibody and its preparation provided by the present invention have the following excellent effects:
  • the anti-C5a antibody of the present invention can significantly reduce the expression of CD11b in human neutrophils induced by endogenous C5a, does not inhibit plasma hemolytic activity, and can significantly reduce the cytokine storm and inflammatory response caused by the new coronavirus in vivo .
  • the anti-C5a antibody preparation of the present invention has strong stability under high temperature, light, vibration, freeze-thaw, acceleration and long-term conditions, which can ensure that the preparation maintains good stability during preparation, transportation and storage, and ensures the safety of clinical medication and quality controllability.
  • Figures 1A-1B show the results of CD11b blocking experiments.
  • the results in Figure 1A show that in human neutrophils, anti-C5a antibodies Cab42, Cab44, and Cab45 can block the upregulation of CD11b induced by human endogenous C5a.
  • the results in Figure 1B show that compared with the control antibody INab308, the anti-C5a antibody Cab42 can block the up-regulation of CD11b expression induced by endogenous human C5a in human neutrophils even if there is more than 50 times the molar amount of C5 in the reaction system.
  • Figures 2A-2B show plasma hemolytic activity of C5a antibody.
  • anti-C5a antibodies Cab35, Cab42, Cab44, Cab45 did not inhibit plasma hemolytic activity compared with the control antibody Eculizumab.
  • anti-C5a antibodies Cab35, Cab42, Cab44, Cab45 did not inhibit plasma hemolytic activity compared to the control antibody Eculizumab.
  • reagents used in the following examples are prepared by conventional methods or obtained from commercial sources; the experimental methods used, if not specified, are conventional methods; the materials, instruments, etc. used, Unless otherwise specified, all were obtained from commercial sources.
  • V H and V L fragments were respectively amplified with specific primers for human V H and V L.
  • V H was synthesized by a linker
  • V L were spliced into scFv form, and then inserted into the yeast display plasmid PYD1, and the yeast was electroporated to obtain the yeast display human antibody scFv library.
  • the natural yeast display human antibody scFv library was enriched by MACS magnetic bead sorting with biotinylated C5a.
  • the yeast library was transferred to a phage display system. Continue to use C5a to screen the phage for three rounds, and then select a single clone for binding ELISA identification and in vitro biological activity evaluation to obtain the lead antibody.
  • the human germline gene with the closest relationship to the maternal sequence was used as a template, and combined with structure prediction analysis, the amino acid sequence of the non-germline gene in the framework region of the maternal sequence was restored to mutation It is the amino acid sequence of the germline gene, thereby improving the human origin of the candidate molecule.
  • affinity maturation isomerization risk points are removed, and Fc is modified to obtain Cab35, Cab42, Cab44, and Cab45 antibodies.
  • the above four antibodies were expressed and purified for subsequent experiments.
  • the amino acid sequence of the heavy chain constant region of Cab35, Cab42, Cab44, and Cab45 antibodies is shown in SEQ IN NO: 26, and the amino acid sequence of the light chain constant region is shown in SEQ IN NO: 28.
  • the specific amino acid sequence of the antibody is shown in the table below.
  • Upregulation of CD11b expression is a characteristic and sensitive marker of neutrophil activation, and the level of CD11b in neutrophils is used to evaluate the activation of neutrophils.
  • the present invention uses a human whole blood model and uses INab308 (WO2011063980A1, InflaRx) as a control to evaluate the blocking activity of antibodies Cab42, Cab44 and Cab45 on endogenous human C5a.
  • Human whole blood was incubated with human C5a alone or in combination with human C5a and different concentrations of each antibody. After incubation, stain with detection antibody CD11b:FITC, and after lysing red blood cells, analyze CD11b MFI by flow cytometry to reflect the activation level of neutrophils in the blood.
  • both the control antibody INab308 and antibody Cab42 can inhibit the expression of CD11b in human neutrophils induced by endogenous C5a, even in the reaction system In the presence of 50-fold more C5, antibody Cab42 reduced endogenous C5a-induced upregulation of CD11b expression in human neutrophils with greater potency than control antibody INab308.
  • Antibody eC5a IC50(nM) eC5a+50*C5 IC50(nM) Cab42 2.05 31.04 INab308 1.95 42.53
  • the complement system can be activated independently by three activation pathways, which eventually form the membrane attack complex. Under certain experimental conditions, it can directly attack the cell membrane of red blood cells, resulting in lysis of red blood cells. Based on this mechanism, the present invention conducted experiments to evaluate whether the C5a antibody of the present invention would affect the biological activity of C5 convertase to cleave C5 to generate C5b.
  • 50% complement hemolysis assay is a method to measure the total classical complement activity in serum.
  • the assay is a lysis assay in which antibodies are used as activators of the classical complement pathway to sensitize red blood cells and the test serum is diluted to different concentrations to determine the amount required to achieve 50% lysis (CHSO).
  • CHSO 50% lysis
  • the hemolysis rate can be measured with a spectrophotometer.
  • the 50% complement hemolysis assay provides an indirect measure of terminal complement complex (TCC) formation, since the TCC itself has a direct effect on the hemolysis measured. This experiment is well known and routinely performed by those skilled in the art, for example, as described in Limei Zhao et al. Front Immunol. 2017 May 31; 8:636; Zhao et al. Parasites & Vectors. 2014 Feb 24; 7:80 .
  • guinea pig erythrocytes were prepared by centrifugation from fresh guinea pig whole blood and then sensitized with sheep anti-erythrocyte antibody. The above operations can activate the classical hemolytic pathway of complement, causing red blood cell lysis. Absorbance was read at 412nm. The C5 antibody Eculizumab was used as a control.
  • C5a antibody in the complement-mediated alternative pathway activation: Briefly, in the absence of antibody sensitization, rabbit erythrocytes can activate the alternative pathway to form membrane attack complexes, leading to lysis of rabbit erythrocytes. After adding ethylene glycol diaminotetraacetic acid (EGTA) to the reaction system, the substance can chelate Ca 2+ in plasma, but has a weak binding ability to Mg 2+ , so the classical pathway is blocked. The 50% complement hemolysis assay described above was used to measure activation of the alternative pathway. The C5 antibody Eculizumab was used as a control.
  • EGTA ethylene glycol diaminotetraacetic acid
  • the anti-C5a antibody of the present invention neither affects the function of C5b in the classical complement-mediated activation pathway nor affects the function of C5b in the alternative activation pathway.
  • Example 4 In vivo effect of anti-C5a antibody in treating ARDS caused by coronavirus
  • An ARDS animal disease model is constructed to evaluate the therapeutic effect of the anti-C5a antibody of the present invention in vivo.
  • ARDS animal disease model and normal control group A total of 46 C5a humanized mice (purchased from Shanghai Southern Model Biotechnology Co., Ltd.) were used, and the feeding conditions were room temperature 20°C-26°C, relative humidity 40%-70% , 12 hours alternating light and dark.
  • mice 4 days, 3 days and 2 days before the experiment, 40 mice were injected with adenovirus carrying and expressing SARS-CoV-2N protein (see: Ting Gao et al., Highly pathogenic coronavirus N protein aggravates lung injury by MASP -2-mediated complement over-activation medRxiv 2020.03.29.20041962; https://doi.org/10.1101/2020.03.29.20041962), 7.5 ⁇ 10 8 PFU/100 ⁇ L/mouse/time/day, and the remaining 6 mice were injected with Sodium chloride solution (as a normal control group). On day 0 (the day of the experiment), mice were injected with corresponding doses of antibody or sodium chloride solution in groups as follows.
  • mice were injected with LPS-K235 (Sigma-Aldrich) at a concentration of 1 mg/mL, 100 ⁇ L/mouse.
  • LPS-K235 Sigma-Aldrich
  • sodium chloride solution was injected. All reagents in this experiment were administered by tail vein injection. This experiment was performed under the approval of the Ethics Committee of the Beijing Institute of Biotechnology and complied with relevant regulatory standards.
  • Detection of survival rate observe and analyze the survival of mice in each group at 12h, 24h, 36h, 48h, 60h and 72h after administration.
  • White blood cell count 72 hours after administration, the mice were anesthetized, and blood was collected from the orbit. use A series of blood analyzers can count and classify white blood cells, including white blood cell count (WBC), neutrophils (Neut), lymphocytes (Lymph), and monocytes (Mono).
  • WBC white blood cell count
  • Neut neutrophils
  • Lymph lymphocytes
  • Mono monocytes
  • Inflammatory cytokine results Compared with the normal control group, the levels of GM-CSF, IL-1 ⁇ , IL-6, TNF- ⁇ , and MCP-1 in the model control group were significantly increased, and the differences between the two were statistically significant. Scientific significance (P ⁇ 0.05). Compared with the model control group, GM-CSF, IL-1 ⁇ , IL-6, TNF- ⁇ , MCP-1, C5a in the experimental group administered with 3 doses of different anti-C5a antibodies (Cab35, Cab42, Cab44 or Cab45) The levels were decreased in a dose-dependent manner. Moreover, the levels of most of these cytokines had statistically significant differences between the dosage experiment group and the model group (P ⁇ 0.05). The above results show that the anti-C5a antibody of the present invention can significantly reduce the cytokine storm and inflammatory response caused by the novel coronavirus in vivo.
  • Embodiment 5 preparation of anti-C5a antibody preparation
  • the anti-C5a antibody preparation prescription is as follows:
  • Embodiment 6 anti-C5a antibody preparation stability test
  • Test items include visible foreign matter, concentration, turbidity, pH, osmotic pressure, viscosity, biological activity, thermal stability, insoluble particles, aggregation characteristics, degradation characteristics and charge heterogeneity of antibody preparations.
  • the characteristics of the polymer were detected by the SEC method and the NR-CE-SDS method, and the charge heterogeneity was detected by the CEX method.
  • each formulation of each antibody was tested under high temperature conditions (40°C ⁇ 2°C, 75% ⁇ 5% RH (relative humidity), 0 days, 1 week, 2 weeks, 3 weeks).
  • Table 6 shows the test results of each preparation of the exemplary Cab35 antibody: relative to day 0, the visible foreign matter, concentration, turbidity, pH, osmotic pressure, viscosity, biological activity, thermal stability,
  • the insoluble particles basically did not change; aggregates and fragments increased slightly, and the main peak decreased slightly; the range of aggregates detected by SEC was within 0.9%; the range of aggregates detected by NR-CE-SDS was within 0.8%, and the range of changes of the main peak was 2.7% Within , the range of fragment variation is within 2.0%.
  • the above results indicate that the preparation of Cab35 has good stability under high temperature conditions.
  • each antibody preparation was tested under light conditions (5°C ⁇ 3°C, 4500 ⁇ 500lx, 5W/m 2 , 0 day, 3 days, 5 days, 1 week, 2 weeks of light).
  • Table 7 shows the test results of each preparation of the exemplary antibody Cab42 (IgG1 mutation): within 2 weeks of light, relative to day 0, the visible foreign matter, concentration, pH, osmotic pressure, viscosity, and biological activity of the antibody preparation , thermal stability, and insoluble particles basically did not change; aggregates and fragments increased slightly, and the main peak decreased slightly: the range of aggregates detected by SEC was within 3.10%; the range of aggregates detected by NR-CE-SDS was within 1.9%, and the main peak The range of variation is within 4.4%, and the range of fragment variation is within 2.5%.
  • the above results show that the Cab42 (IgG1 mutation) antibody preparation can basically remain stable under light conditions.
  • each antibody preparation was tested under shaking conditions (5°C ⁇ 3°C, 100rpm shaking for 0 days, 1 week, and 2 weeks).
  • Table 8 shows the test results of each preparation of the exemplary antibody Cab44: within 2 weeks of shaking, relative to day 0, the visible foreign matter, concentration, turbidity, pH, osmotic pressure, viscosity, biological activity, Thermal stability and insoluble particles basically did not change; SEC detection aggregates had a small change range, all within 0.13%; CEX detection acid peak, main peak and basic peak change range were all within 0.40%, almost no change; NR- CE-SDS aggregates, main peaks and fragments vary within 0.42%, almost no change. The above results demonstrate the excellent stability of the formulation of the Cab44 antibody under shaking conditions.
  • Table 9 shows the test results of each preparation of the exemplary antibody Cab45 (IgG1 mutation): within 5 times of freezing and thawing, compared with 0 times of freezing and thawing, foreign matter, concentration, turbidity, pH, osmotic pressure can be seen in each antibody preparation , viscosity, biological activity, thermal stability, and insoluble particles basically did not change; the aggregates detected by SEC changed very little, all within 0.15%; Changes; NR-CE-SDS detected aggregates, main peaks and fragments within 0.39%, almost no change.
  • the above results demonstrate the excellent stability of the formulation of the Cab45 (IgG1 mutant) antibody under freeze-thaw conditions.
  • each antibody preparation was tested under accelerated conditions (25°C ⁇ 2°C, 60% ⁇ 10%RH (relative humidity) for 0 days, 2 weeks, 1 month, and 2 months).
  • Table 10 shows the test results of each preparation of the exemplary antibody Cab42 (IgG1 mutation): within 2 months of acceleration, relative to day 0, visible foreign matter, concentration, turbidity, pH, osmotic pressure, viscosity of the antibody preparation , activity, thermal stability, and insoluble particles basically did not change; SEC detected polymers did not change or changed very little, and the range of change was within 0.31%; CEX detected acid peaks and base peaks increased slightly, and the main peak decreased slightly; Within 3.10%, the change range of the base peak is within 0.9%, and the change range of the main peak is within 4%; the increase range of the aggregate detected by NR-CE-SDS is within 0.5%, the decrease range of the main peak is within 1%, and the increase range of the fragment is within 0.5%. .
  • the above results indicate that the preparation of the Cab42 (IgG1 mutant) antibody can be basically stable under accelerated conditions.
  • the results of the accelerated test show that the anti-C5a antibody preparation of the present invention has no significant change under accelerated conditions and can basically remain stable.
  • the stability of the antibody preparation was tested under long-term conditions (5°C ⁇ 3°C for 0 days, 2 weeks, 1 month, 2 months, 3 months, and 6 months).
  • Table 11 shows the test results of each preparation of the exemplary antibody Cab44: within 6 months under long-term conditions, relative to day 0, visible foreign matter, concentration, turbidity, pH, osmotic pressure, viscosity, activity of the antibody preparation , thermal stability and insoluble particles are basically unchanged; SEC detects that the change range of aggregates is within 0.11%, almost no change; The range of change is within 0.49%, and the range of change of the basic peak is within 0.13%.
  • NR-CE-SDS detects that there is almost no change in the aggregate, main peak, and fragment. The increase of the aggregate is within 0.5%, and the decrease of the main peak is within 0.5%. The increase is within 0.3%.
  • the above results demonstrate the excellent stability of the formulation of the Cab44 antibody under long-term conditions.
  • the anti-C5a antibody preparation of the present invention has strong stability under high temperature, light, shaking, freeze-thaw, acceleration and long-term conditions, which can ensure that the preparation maintains good stability during preparation, transportation and storage, and ensures Clinical drug safety and quality controllability.

Abstract

L'invention concerne un anticorps C5a isolé pour le traitement de maladies et de troubles médiés par C5a. L'invention concerne en outre une préparation d'anticorps anti-C5a. La préparation présente une forte stabilité dans des conditions de température élevée, de lumière, d'oscillation, de congélation-décongélation, d'accélération et à long terme, ce qui peut garantir que la préparation conserve une bonne stabilité pendant la préparation, le transport et le stockage, et assure la sécurité et la contrôlabilité de la qualité du médicament clinique.
PCT/CN2022/139676 2021-12-22 2022-12-16 Anticorps anti-c5a isolé, sa préparation et son utilisation WO2023116574A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202280008248.5A CN116670288A (zh) 2021-12-22 2022-12-16 一种分离的抗C5a抗体及其制剂与应用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202111578707 2021-12-22
CN202111578707.7 2021-12-22

Publications (1)

Publication Number Publication Date
WO2023116574A1 true WO2023116574A1 (fr) 2023-06-29

Family

ID=86901300

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/139676 WO2023116574A1 (fr) 2021-12-22 2022-12-16 Anticorps anti-c5a isolé, sa préparation et son utilisation

Country Status (3)

Country Link
CN (1) CN116670288A (fr)
TW (1) TW202334230A (fr)
WO (1) WO2023116574A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088247A2 (fr) * 2010-12-22 2012-06-28 Medimmune, Llc Fragments et anticorps anti-c5/c5a/c5adesr
CN102741283A (zh) * 2009-11-26 2012-10-17 因弗拉克斯有限责任公司 具有高阻断活性的抗-C5a结合部分
CN103201289A (zh) * 2010-04-30 2013-07-10 阿雷克森制药公司 抗-c5a抗体和使用所述抗体的方法
CN114364695A (zh) * 2020-06-24 2022-04-15 舒泰神（北京）生物制药股份有限公司 特异性识别c5a的抗体及其应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102741283A (zh) * 2009-11-26 2012-10-17 因弗拉克斯有限责任公司 具有高阻断活性的抗-C5a结合部分
CN103201289A (zh) * 2010-04-30 2013-07-10 阿雷克森制药公司 抗-c5a抗体和使用所述抗体的方法
WO2012088247A2 (fr) * 2010-12-22 2012-06-28 Medimmune, Llc Fragments et anticorps anti-c5/c5a/c5adesr
CN114364695A (zh) * 2020-06-24 2022-04-15 舒泰神（北京）生物制药股份有限公司 特异性识别c5a的抗体及其应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEN GUOJIANG, YANG YUEMEI, GAO XUDONG, DOU YAN, WANG HUIHUI, HAN GENCHENG, WANG RENXI, WANG JIANAN, WANG LIYAN, LI XINYING, GUO R: "Blockade of complement activation product C5a activity using specific antibody attenuates intestinal damage in trinitrobenzene sulfonic acid induced model of colitis", LABORATORY INVESTIGATION, NATURE PUBLISHING GROUP, THE UNITED STATES AND CANADIAN ACADEMY OF PATHOLOGY, INC., vol. 91, no. 3, 1 March 2011 (2011-03-01), The United States and Canadian Academy of Pathology, Inc. , pages 472 - 483, XP093073768, ISSN: 0023-6837, DOI: 10.1038/labinvest.2010.183 *
P J VLAAR, DE BRUIN S, BULLE E B, F E, VAN H P, MD BAARLE, SCHULTZ M J, HORN J, PAULUS F, BOS L D, VAN E, MD ZEGGEREN, KONING R, : "Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial", LANCET RHEUMATOL, vol. 2, 28 September 2020 (2020-09-28), pages e764 - 773, XP055760230 *

Also Published As

Publication number Publication date
CN116670288A (zh) 2023-08-29
TW202334230A (zh) 2023-09-01

Similar Documents

Publication Publication Date Title
JP6224059B2 (ja) 補体のインヒビターによる発作性夜間血色素尿症患者の処置
US20210130451A1 (en) Treatment for rheumatoid arthritis
US7820617B2 (en) Methods of selecting immunoregulator peptides obtained from gonadotropins
US20110142837A1 (en) Method Of Treating Acute Respiratory Distress Syndrome
EP3085385B1 (fr) Composition pharmaceutique contenant de l'adalimumab
CN110354073B (zh) 一种免疫抑制剂单克隆抗体的液体制剂
JP2010509338A (ja) 溶血性貧血を処置する方法
JP2015522524A (ja) 抗体製剤
WO2023116574A1 (fr) Anticorps anti-c5a isolé, sa préparation et son utilisation
US20200254107A1 (en) Use of high molecular weight polyethylene glycol compositions to restore the efficacy of pegylated therapeutic compositions
US20240010681A1 (en) Peptides and methods of use
US20240131172A1 (en) Use of high molecular weight polyethylene glycol compositions to restore the efficacy of pegylated therapeutic compositions
WO2023138499A1 (fr) Préparation d'anticorps pour reconnaître spécifiquement le récepteur du facteur de stimulation des colonies de granulocytes-macrophages et son utilisation
WO2024057232A1 (fr) Anticorps, compositions et méthodes de traitement
NZ744721A (en) Treatment for rheumatoid arthritis
NZ744721B2 (en) Treatment for rheumatoid arthritis

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 202280008248.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22909887

Country of ref document: EP

Kind code of ref document: A1